Results of minimally invasive approach for rheumatic mitral valve disease
© Kanhere et al. 2015
Published: 16 December 2015
The rapid development and refinement of techniques over the past decade have led to the realization that a Minimally invasive (MI) approach enables complex (open) valve surgery to be performed with results equivalent to those of conventional valve surgery done in experienced center. Rheumatic Heart Disease (RHD) continues to be endemic in developing countries like India.
To compare minimally invasive surgery with standard sternotomy procedure among patients of rheumatic mitral valve disease.
A retrospective comparative study was carried out in tertiary care hospital of central India. From April 2013 to December 2014, a total of 128 eligible study subjects (45 males and 83 females) [range 7 to 66 years] presented to CVTS department of our hospital were included. Majority of were in NYHA III (52.9%) and NYHA IV (29.7%). All study subjects were considered for minimally invasive (MI) approach, however only 63 study subjects fulfilled the eligibility criteria for the above procedure. Clamp time (CT), Cardiopulmonary bypass (CPB) time, intensive care unit (ICU) stay and hospital stay was observed among study subjects. These results were compared to 63 age and sex matched study subjects from 2012 and also with 65 study subjects who had not undergone minimally invasive surgery from the same period.
Among MI surgery, operative mortality was 02 (3%), re-exploration were 3 (5%) and 3 (5%) re-admission. 01 re-admission was for delayed tamponade and 02 were for non-compliance with oral anticoagulants. Statistically significant lower CT, CPB time and ICU stay was found in minimally invasive surgery when compared with standard sternotomy approach (p < 0.006).
Minimally invasive approach for rheumatic valve yields similar morbidity and mortality with reduced surgical time and length of ICU stay. Peripheral cannulation does not cause problem and cosmetic results were excellent.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.